Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Defibrillators”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,387 records · Page 77Linked to original sources
PubMed2001

An investigation of the importance of myocardial anisotropy in finite-element modeling of the heart: methodology and application to the estimation of defibrillation efficacy.

Finite-element (FE) modeling has been widely used in studies of bioelectric phenomena of tissues, including ventricular defibrillation. Most FE models, whether built from anatomical atlases or subject-specific tomographic images, treat the myocardium as an isotropic tissue. However, myocardium has been experimentally shown to have significant anisotropy in its resistivities, although myocardial fiber directions are difficult to measure on a subject-specific basis. In this paper, we: 1). propose a method to incorporate a widely known myocardial fiber direction model to a specific individual and 2). assess the effects of myocardial anisotropy on myocardial voltage gradients computed for a study of implantable defibrillators. The thoracic FE model was built from CT images of a young pig, and the myocardial fiber structures were incorporated via elastic mapping. Our results demonstrate a good mapping of geometry between the source and target hearts with an average root-mean-square error of less than 2.3 mm and a mapped fiber pattern similar to those known to exist in vivo. With the mapped fiber information, we showed that the estimated minimal myocardial voltage gradient over 80% of the myocardium differs by less than 10% between using an isotropic and anisotropic myocardial models. Thus, myocardial anisotropy is expected to have only a small effect on estimates of defibrillation threshold obtained from computed voltage gradients. On the other hand, anisotropy may be essential if defibrillation efficacy is analyzed by transmembrane voltage of the myocardial cells.

Animals↗
PubMed1981

Pacemaker failure following external defibrillation.

An 81-year-old female with the sick sinus syndrome had a permanent pacemaker implanted. She subsequently developed ventricular fibrillation and was successfully defibrillated. However, the defibrillation paddle was placed on the pulse generator which led to a complete loss of function of the pulse generator. External defibrillation can produce varying degrees of damage to the implanted pulse generator. The resultant abnormalities are discussed and recommended defibrillation procedures are also outlined in this report.

Aged↗
PubMed1988

Strength-duration curves of fixed pulse width variable tilt truncated exponential waveforms for nonthoracotomy internal defibrillation in dogs.

Six anesthetized dogs (wgt 19.6 + 1.1 kg) underwent defibrillation trials using truncated monophasic pulses of 2.5-20 msec in duration. The current pathway consisted of a 4 cm2 RV catheter electrode (cathode) and a 13.9 cm2 subcutaneous chest wall patch (anode). Fibrillation was induced by alternating current and defibrillation attempted 10 seconds later. Only one test shock was assessed for each fibrillation episode. The various durations were tested randomly, and the minimum peak voltage and energy resulting in defibrillation was determined for each. Shorter pulse durations were associated with lower energies with pulses of 2.5-15 msec having significantly lower energy thresholds than shocks of 20 msec (P less than 0.05). The relationship between duration and voltage threshold is hyperbolic with minimum voltage between 7.5 and 12.5 msec while the shortest and longest pulses were associated with the highest voltage thresholds. Shocks of 5 to 15 msec were associated with significantly lower voltage threshold than 2.5 msec pulses (P less than 0.05). The threshold average current (Iav) reached a nadir at 10 msec. Shocks in the midrange of those tested resulted in the best combination of low average current and energy requirements for defibrillation using this nonthoracotomy lead system.

Animals↗
PubMed1988

Increased pacing threshold after an automatic defibrillator shock in dogs: effects of class I and class II antiarrhythmic drugs.

A high energy shock delivered by an automatic defibrillator may interfere with pacemaker function. To provide insight into the changes that occur in the threshold for ventricular pacing after the shock from an automatic defibrillator, we measured the time to capture during asynchronous ventricular pacing in dogs from endocardial or epicardial sites, after a 30 joule shock was delivered via conventional automatic defibrillator (AICD) patch electrodes. After a 30 joule shock, there was a transient loss of ventricular capture. The duration of capture loss was related to current strength. During endocardial pacing at threshold current, the time to capture was 4.9 +/- 1.2 s, whereas at current values twice threshold the time to capture from endocardial pacing was 2.2 +/- 0.9 s. No difference was found between endocardial and epicardial pacing sites in the time to capture. To ascertain the mechanism of capture loss we: (1) examined the effects of converting the pacing catheter to a current sink (transiently shunting to ground); (2) altered excitability by an infusion of flecainide; (3) blocked sympathetic input (propranolol). No change in time to capture was noted by shunting the pacer to ground. After an infusion of flecainide the time to capture from endocardial pacing was significantly prolonged to 14.9 +/- 2.2 s at the threshold value (P less than .01) and 5.6 +/- 2.1 s at twice threshold (P less than .05). Conversely, intravenous propranolol had no effect on the time to capture after shock from endocardial pacing. These data indicate that there is a transient increase in pacing threshold after the shock from an automatic defibrillator.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1991

Implantable cardioverter defibrillator implanted by nonthoracotomy approach: initial clinical experience with the redesigned transvenous lead system.

Standard implantation procedure for the implantable cardioverter defibrillator (ICD) has traditionally required a thoracotomy approach. A newly revised nonthoracotomy defibrillator lead system that uses a single transvenous tripolar endocardial lead alone or in combination with a subcutaneous/submuscular patch lead was introduced into clinical trials in September, 1990. Fourteen patients requiring a cardioverter defibrillator for recurrent sustained ventricular tachycardia (eight patients) or aborted sudden cardiac death (six patients) were evaluated for implantation of this lead system. Primary successful lead system implantation was obtained in nine patients. The remaining five patients had unacceptably high defibrillation thresholds (DFTs) for implantation. One of the nine initially successful implants demonstrated unacceptable DFTs and cross-talk inhibition from a permanent pacemaker necessitating removal of the nonthoracotomy lead system and replacement with a conventional lead system via thoracotomy. All remaining primary implanted patients experienced successful conversion of induced ventricular fibrillation prior to hospital discharge. Continued follow-up and greater experience to confirm the durability and efficacy of the nonthoracotomy AICD lead system are needed.

Aged↗
PubMed1991

Effects of lidocaine on defibrillation threshold in the pig: evidence of anesthesia related increase.

Some antiarrhythmic drugs may influence the ability of a shock to defibrillate a patient but the effect of lidocaine on defibrillation efficacy has been controversial, suggesting multiple influencing factors. We determined the effects of three doses of lidocaine on defibrillation thresholds, using single and sequential shocks, in 36 open chest halothane-anesthetized pigs. An additional eight pigs were anesthetized with barbiturate and received the highest infusion regime of lidocaine. Shocks were delivered through three mesh electrodes sutured over the anterior right ventricle, posterior right ventricle, and lateral left ventricle for sequential pulse shocks and between a lateral right to a lateral left ventricular mesh electrode for single pulse shocks. Triplicate defibrillation thresholds (DFTs) were obtained before and after lidocaine (n = 32) or saline (n = 12) administration, either with halothane or barbiturate anesthesia. Lidocaine did not alter DFT at any dose with either the single pulse (control 17.4 +/- 3.7 joules [J], highest dose of lidocaine 13.5 +/- 1.7 J, P = NS) or sequential pulse shocks (control 7.6 +/- 0.8 J, highest dose lidocaine 6.6 +/- 0.7 J, P = NS), when halothane anesthesia was used. Similar results were obtained with lower doses. In contrast, lidocaine in pentobarbital anesthetized pigs produced a significant increase of the DFT with single (control 13.7 +/- 1.9, during lidocaine 16.6 +/- 3.1, P less than 0.01) and sequential shocks (control 11.1 +/- 2.2, during lidocaine 14.5 +/- 3.4, P less than 0.01). Interaction between barbiturates and lidocaine, and/or pH may account for the inconsistency in previous studies and must be considered for animal and clinical experiments.

Anesthesia↗
PubMed1991

Safety of external cardioversion/defibrillation in patients with internal defibrillation patches and no device.

Placement of prophylactic epicardial defibrillation patches at time of open-heart surgery in patients at risk for postoperative arrhythmias has been strongly questioned. Concern has centered on the ability to safely perform subsequent external defibrillation if needed. From 61 patients who were treated with a two-stage strategy we identified 17 who, while wearing epicardial patches and no generator, received external cardioversion/defibrillation for 20 episodes of hemodynamically unstable ventricular arrhythmias. All the patients had one small and one large patch. Eighteen of the episodes were induced during electrophysiological testing (with transthoracic shocks delivered via pad electrodes oriented in an apex-posterior configuration) and two were spontaneous. The episodes occurred at 21 +/- 27 days from patch implant. Thirteen episodes (65%) were converted with one shock at an energy level of 185 +/- 65 J. Seven (35%) required a second shock at 351 +/- 22 J. The accumulated energy requirement was 286 +/- 205 J. No adverse outcomes were noted. The number of episodes requiring more than one shock and the energy requirements were not different from those in a control group of 20 similar arrhythmias treated with the same equipment. Under these conditions, external cardioversion/defibrillation in patients with one large and one small epicardial defibrillation patch was uniformly successful. Further data is needed in the out-of-hospital setting and on the results of external defibrillation in patients with two large patches.

Adult↗
PubMed1991

Defibrillation with low voltage using a left ventricular catheter and four cutaneous patch electrodes in dogs.

The purpose of this study was to determine a lower limit of defibrillation thresholds (DFTs) that could be used to evaluate nonthoracotomy lead configurations for implantable defibrillators. A lead configuration that consisted of a left ventricular catheter and four circumferential cutaneous patches was tested because it was hypothesized to create a relatively uniform electric field for defibrillation. In eight anesthetized dogs, three 8F defibrillating catheters with 6 cm platinum clad titanium tips were inserted into the right ventricle (R), right ventricular outflow tract (O), and left ventricle (L). Four cutaneous patch electrodes (4P), each with a surface area of 42 cm2, were placed on the left lateral, right lateral, anterior and posterior thorax. DFTs for ten lead configurations, consisting of different combinations of these electrodes, were evaluated. DFTs were determined by using a modified Purdue technique and applying a single capacitor biphasic shock with both phases 6 ms in duration after 15 sec of electrically induced fibrillation. The L(-)----4P+ configuration produced a lower DFT than R(-)----4P+ (3.2 +/- 1.6 J vs 8.0 +/- 4.2 J, P less than 0.001) with reduced current (2.6 +/- 0.7 A vs 4.1 +/- 1.2 A, P less than 0.001). Lowering the impedance by a mean of 40%, configurations that used four patches produced lower DFTs than those that used a single left lateral patch. The use of an O catheter produced lower DFTs only when used in conjunction with an R catheter.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1991

Long-term community hospital experience with the internal defibrillator.

Seventy-seven patients with drug refractory ventricular tachycardia (57) and ventricular fibrillation (20) received the implantable defibrillator. There were 55 men and 22 women with a mean age of 63 +/- 10 years. The anatomical diagnoses were coronary artery disease in 61 patients, cardiomyopathy in 15 patients, and aortic stenosis in one patient. The mean ejection fraction was 32 +/- 12%. Concurrent surgery at defibrillator implantation was coronary bypass in eight patients and aortic valve replacement in one patient. There were no intraoperative mortalities. The mean ventricular fibrillation termination threshold was 13 +/- 6 joules. During a follow-up period of 16 +/- 10 months (range 2-40 months) four patients died: electrical mechanical dissociation (two patients), respiratory failure, and sepsis. Thirty-eight patients (51%) continued receiving antiarrhythmic drug therapy, with quinidine sulfate and procainamide being the most frequently utilized agents. Fifty-four patients (72%) have received a mean of 9 +/- 10 shocks (range 1-44). Implantable defibrillators are often needed in patients seen in large community hospitals. This technology can be administered successfully in this setting with complications and results comparable to those reported from university hospitals. Implantable defibrillators are effective in preventing arrhythmic death and can be used with low risk to the patients.

Anti-Arrhythmia Agents↗
PubMed1991

The impact of antitachycardia pacing with defibrillation.

Chronic recurrent ventricular tachycardia (VT) can be reproducibly terminated by programmed endocardial right ventricular stimulation. However, antitachycardia pacing can be associated with possible acceleration of VT, while frequent episodes of VT and patient discomfort can limit treatment by an implantable cardioverter defibrillator (ICD). The combined use of antitachycardia pacing and the AICD (automatic implantable cardioverter defibrillator) was evaluated in 6 out of 51 patients (age 57 +/- 11 years) in whom the AICD had been implanted because of recurrent VT. In each instance VT could be terminated by temporary overdrive pacing. The interactive mode of VT termination by a pacemaker (Tachylog) as well as by the AICD was assessed after implantation. In the automatic mode, the Tachylog functioned as a bipolar, ventricular inhibited (VVI) device with antitachycardia burst stimulation capability, allowing two to five stimuli at intervals of 260-300 ms and one or two interventions. During follow-up of 47 +/- 24 months, the Tachylog terminated VT reliably 50-505 times per patient. When burst stimulation accelerated VT, termination was achieved by AICD discharge. Thus, drug resistant VT can be terminated by antitachycardia pacing to avoid patient discomfort. In the event of tachycardia acceleration, VT was terminated by the AICD. A universal pacemaker-defibrillator should combine antibradycardia and antitachycardia pacing with back-up cardioversion defibrillation.

Combined Modality Therapy↗
PubMed1991

Comparison between two versus three patches single pulse shock defibrillation in pigs.

The aim of the study was to test the hypothesis that defibrillation with a single pulse shock can be obtained at lower energy using three epicardial patches configuration (one cathode and two anodes) instead of the conventional two patches. The total surface area of the two- and three-patches configuration was the same (10 cm2 vs 9.9 cm2). Epicardial spatial configuration was planned by using a computerized heart model. In ten anesthetized open-chest pigs, ventricular fibrillation was induced by using AC current through the mesh plaque epicardial custom-designed electrodes, and the minimum energy requirement for defibrillation was determined 15 seconds after the onset of stable ventricular fibrillation. Results were as follows (mean +/- standard deviation): Defibrillation Threshold 16 +/- 9 J 9 +/- 5 J P less than 0.01 CONCLUSIONS: three epicardial patches configuration significantly reduces energy requirements for defibrillation compared with two patches when single pulse shock is used.

Animals↗
PubMed1991

Implantable pharmacological defibrillator (AIPhD): preliminary investigations in animals.

The treatment of ventricular fibrillation (VF) by means of automatic implantable cardioverter defibrillators (AICD) poses many severe problems and limitations at the present time. In order to overcome these problems, we propose a totally new way to terminate VF or ventricular sustained tachycardia (VST). Our proposal consists of replacing the electric shock, which is dangerous, delayed, and sometimes ineffective, with a "chemical" shock: i.e., a chemical bolus retroperfused in the coronary sinus (CS) immediately after VF arises. The possible device is hypothesized and preliminary investigations in animals, performed to verify the theoretical assumption, are presented. In rabbits, and in larger animals (sheep and swine). Drugs were perfused in the coronary bed: lidocaine was used in 86% and bretylium tosylate in 14% of the animals. The results were: lidocaine immediately terminated VF in 100% and sinus rhythm was restored in rabbits; lidocaine terminated VF in VST in sheep; and in swine, bretylium immediately produced sinus rhythm in one case; in another one, only delayed sinus rhythm was achieved but lasted a short time; in the last case ventricular tachycardia at 128 beats/min appeared. Because new drugs, which are really "defibrillating" drugs, are available (bretylium tosylate, bethanidine, clofilium, tricyclic antidepressants, phenotiazine derivatives), we plan to investigate these defibrillating drugs in isolated hearts, found in suitable animals like dogs (sheep and swine are difficult to defibrillate) and in humans during routine electropharmacological studies.

Animals↗
PubMed1992

Analysis of deaths in patients with an implantable cardioverter defibrillator.

The cause of death and clinical characteristics of 26 patients that died after implantable cardioverter defibrillator placement were reviewed and compared to the 145 patients still living after a mean follow-up of 17 months. Operative mortality was 4% (7/171) and resulted from postoperative ventricular arrhythmias (four patients), heart failure (two patients), and respiratory failure (one patient). Operative mortality was significantly higher (1.7% vs 9.6%, P less than 0.05) following concomitant surgical procedures. Total late mortality was 11% (18/171). Thirteen deaths (75%) occurred in-hospital from progressive deterioration of left ventricular function (nine patients), arrhythmia (two patients), and noncardiac causes (two patients). Outpatient mortality was 3.5% (6/171) and resulted from presumed sudden cardiac death in five of six patients; two of the five had devices that were inactive, one had high defibrillation thresholds, and two had suspected bradyarrhythmic deaths. One postoperative death and one late in-hospital death were also considered sudden cardiac deaths for a total of seven patients with defibrillation system failures. By multivariant analysis, preoperative clinical characteristics associated with a worse prognosis following defibrillator implantation were identified: presentation as ventricular tachycardia (P less than 0.02), induction of sustained monomorphic ventricular tachycardia (P less than 0.05), poor left ventricular performance (P less than 0.01), poor functional status (P less than 0.001), and the use of diuretics (P less than 0.01). Frequent device discharges (P less than 0.001) and concomitant antitachycardia pacing systems (P less than 0.001) were markers for greater arrhythmia recurrence and were potent predictors of a worse prognosis and particularly sudden death.

Arrhythmias, Cardiac↗
PubMed1992

Clinical evaluation of the safety of repetitive intraoperative defibrillation threshold testing.

One goal of the initial implantation procedure for a cardioverter defibrillator is determination of the configuration and patch location with the lowest defibrillation threshold (DFT). To determine the safety of multiple defibrillation tests, an analysis of the intraoperative defibrillation threshold tests (DFTT) in our patients was performed. In 84 patients, the mean number of DFT trials was 5.27; the mean number of joules received was 275.0. The maximum number of shocks in one implant procedure was 50 for a total of 4,895 joules without complications. Four patients received 30 or more DFT shocks without complication. There were two complications related directly to the DFTT: one patient with severe noninflammatory cardiomyopathy developed electromechanical dissociation and was subsequently resuscitated and survived; the second patient with severe triple vessel coronary artery disease suffered an intraoperative myocardial infarction during testing and eventually died 22 days postoperatively. All patients received an ICD unit; six patients had DFTs of greater than 20 joules. Based on our experience, we followed the clinical status (heart rate, blood pressure, ECG changes, fluid status, total anesthesia time) during the DFTT to determine the extent and duration of our testing protocol. Multiple shocks due to repositioning of the leads in a stable patient should not prohibit extensive testing as adverse consequences do not appear to be cumulative.

Electric Countershock↗
PubMed1992

Gross and microscopic changes associated with a nonthoracotomy implantable cardioverter defibrillator.

The pathology associated with an investigational transvenous defibrillating and sensing lead is described. The lead system had delivered a total of 865 J from the time of implantation to the time of patient death from a noncardiac cause 7 months after implantation and 1 month after his last defibrillator shock. There was mild, superficial fibrous thickening on the endothelial surface of the superior vena cava adjacent to the proximal spring electrode, which did not extend into the vessel wall. The distal portion of endocardial lead was embedded in the interventricular septum near the apex of the right ventricle, surrounded by fibrous thickening, and partially covered by endocardial tissue. Microscopically, there was a thick bed of fibrous connective tissue surrounding the lead with extensive interstitial fibrous connective tissue radiating into the adjacent myocardium. Since this pattern is different from the more generalized fibrotic scarring produced by myocardial infarction, we speculate that the mechanism for the observed interstitial fibrosis is replacement fibrosis following acute myocyte injury that resulted from prior defibrillator shocks and possibly from the trauma produced by the lead compressing adjacent myocardium during systole. Potential effects on device efficacy of these fibrotic changes at the bioelectric interface include their representing a new arrhythmia substrate, the possibility that fibrosis could increase both defibrillation and pacing thresholds, and that the inflammatory reaction may cause deterioration of intracardiac electrograms and interfere with sensing and tachycardia recognition.

Aged↗
PubMed1994

Lead systems for atrial defibrillation.

In summary, these five studies show that electrode locations that include both left and right atrium result in lower thresholds. Thresholds from right atrium to chest wall patch are higher than thresholds from right atrium to cardiac vein, suggesting that confinement of the electric field by a transvenous electrode system is advantageous. Of the transvenous locations tested, the right atrial appendage to left atrial appendage defibrillation vector consistently had the lowest defibrillation energy threshold. The proximal coronary sinus to right atrial vector may be inappropriate due to the high thresholds observed. The large variability of the mean threshold for the obtuse marginal location in the cardiac vein vasculature suggests that this vector may result in higher thresholds in some instances. Electrode locations that have high defibrillation thresholds and are in close proximity to the sinoatrial or atrioventricular node increase the likelihood of sinus arrhythmias or conduction block following the defibrillation shocks. No difference was detected between the thresholds between the single catheter, two electrode system and the two catheter system, despite the variability of location of the electrode in the right atrium, suggesting that such a catheter may provide a simpler implantation procedure and equivalent thresholds in some patients. These findings suggest that coronary sinus/great cardiac vein catheter designs should strive for implantation in the distal portion of the great cardiac vein so that the shocking electrode underlies the left atrium with the other shocking electrode located in the right atrium.

Animals↗
PubMed1994

Automated precision current delivery: an alternative method for cardiac defibrillation.

Substantial evidence suggests that the current associated with the discharge is a more precise predictor of defibrillation success than is the total energy of the discharge. However, virtually all commercially available defibrillators are calibrated in terms of energy. This article describes an alternative type of experimental defibrillator, which provides a precisely controlled current throughout the discharge waveform, independent of the load presented to the discharge electrodes (or "paddles"). The discharge current waveform is designed to have the classical critically damped sinusoid waveform, identical to that of the traditional energy-based defibrillator when it is properly matched with its ideal load (the heart/thorax combination). The techniques used to obtain a controlled current discharge are discussed in addition to special operational features.

Automation↗
PubMed1996

Improved nonthoracotomy defibrillation based on ventricular fibrillation waveform characteristics.

The heart has been shown to be more susceptible to defibrillation at a higher absolute ventricular fibrillation voltage (AVFV) measured on the surface ECG. This study evaluated in a closed-chest canine model (n = 7) the clinical applicability of using a real-time VF waveform analysis system using an electrogram defined between the generator can and an RV endocardial electrode. Under fluoroscopic guidance, superior vena cava and RV spring coil catheter electrodes were inserted through the external jugular vein. A subcutaneous patch was placed on the left chest. A two-parameter tracking algorithm was used to dynamically identify the high AVFV area, and a biphasic shock was triggered synchronously at the next peak. The performance of this new peak shock method (PSM) was compared to the conventional method of shocking at a fixed time in 175 paired trials. Five shocks per voltage and five voltages per animal were randomized between the two methods to permit the generation of sigmoidal dose response curves for the estimation of 50% (E50), 75% (E75), and 100% (E100) success energies. Induction of VF and discharge voltage were kept constant while energy delivered, impedance (R), and AVFV at the point of shock were measured. Energy (8.63 +/- 0.40 vs 8.64 +/- 0.40 J), R (48.60 +/- 0.30 vs 48.59 +/- 0.30 omega), and current (7.50 +/- 0.18 vs 7.51 +/- 0.16 A) were not significantly different between trials for either the conventional or the PSM. The time from the onset of VF until the defibrillation shock was 7.98 +/- 1.44 seconds. Higher overall successes (46.3% vs 33.1%; P < 0.01) and lower E50, E75, and E100 were observed for the PSM. Finally, the significantly higher AVFV (9.12 +/- 0.32 vs 4.73 +/- 0.34 mV; P < 0.0001) with the peak method suggests that the high VF voltage could be detected as it occurred in real-time. The improved defibrillation success supports the use of this method for nonthoracotomy defibrillation.

Animals↗